Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.
Villemagne VL, Rowe CC, Barnham KJ, Cherny R, Woodward M, Bozinosvski S, Salvado O, Bourgeat P, Perez K, Fowler C, Rembach A, Maruff P, Ritchie C, Tanzi R, Masters CL. Villemagne VL, et al. Among authors: rembach a. Alzheimers Dement (N Y). 2017 Nov 9;3(4):622-635. doi: 10.1016/j.trci.2017.10.001. eCollection 2017 Nov. Alzheimers Dement (N Y). 2017. PMID: 29201996 Free PMC article.
Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease.
Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li QX, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA, Szoeke C, Macaulay L, Rowe CC, Villemagne VL, Ames D, Martins RN, Bush AI, Masters CL; AIBL research group. Rembach A, et al. Alzheimers Dement. 2014 Jan;10(1):53-61. doi: 10.1016/j.jalz.2012.12.006. Epub 2013 Mar 13. Alzheimers Dement. 2014. PMID: 23491263
Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.
Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromey J, Ellis KA, Faux NG, Foster J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ward V, Martins RN, AIBL Research Group. Lui JK, et al. Among authors: rembach a. J Alzheimers Dis. 2010;20(4):1233-42. doi: 10.3233/JAD-2010-090249. J Alzheimers Dis. 2010. PMID: 20413897
Blood-based protein biomarkers for diagnosis of Alzheimer disease.
Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group. Doecke JD, et al. Among authors: rembach a. Arch Neurol. 2012 Oct;69(10):1318-25. doi: 10.1001/archneurol.2012.1282. Arch Neurol. 2012. PMID: 22801742 Free PMC article.
Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease.
Rembach A, Doecke JD, Roberts BR, Watt AD, Faux NG, Volitakis I, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Wilson W, Ellis KA, Martins RN, Rowe CC, Villemagne VL, Ames D, Masters CL, AIBL research group, Bush AI. Rembach A, et al. J Alzheimers Dis. 2013;34(1):171-82. doi: 10.3233/JAD-121474. J Alzheimers Dis. 2013. PMID: 23168449
Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
Ellis KA, Szoeke C, Bush AI, Darby D, Graham PL, Lautenschlager NT, Macaulay SL, Martins RN, Maruff P, Masters CL, McBride SJ, Pike KE, Rainey-Smith SR, Rembach A, Robertson J, Rowe CC, Savage G, Villemagne VL, Woodward M, Wilson W, Zhang P, Ames D; AIBL Research Group. Ellis KA, et al. Among authors: rembach a. Int Psychogeriatr. 2014 Apr;26(4):543-54. doi: 10.1017/S1041610213001956. Epub 2013 Nov 20. Int Psychogeriatr. 2014. PMID: 24252258
Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, Doecke JD; AIBL Research Group. Rembach A, et al. J Alzheimers Dis. 2014;40(1):95-104. doi: 10.3233/JAD-131802. J Alzheimers Dis. 2014. PMID: 24334723
MR-less surface-based amyloid assessment based on 11C PiB PET.
Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Macaulay SL, Ames D, Masters CL, Ellis KA, Villemagne VL, Rowe CC, Fripp J; AIBL Research Group. Zhou L, et al. PLoS One. 2014 Jan 10;9(1):e84777. doi: 10.1371/journal.pone.0084777. eCollection 2014. PLoS One. 2014. PMID: 24427295 Free PMC article.
An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation.
Rembach A, Watt AD, Wilson WJ, Rainey-Smith S, Ellis KA, Rowe CC, Villemagne VL, Macaulay SL, Bush AI, Martins RN, Ames D, Masters CL, Doecke JD; AIBL Research Group. Rembach A, et al. J Neuroimmunol. 2014 Aug 15;273(1-2):65-71. doi: 10.1016/j.jneuroim.2014.05.005. Epub 2014 May 20. J Neuroimmunol. 2014. PMID: 24907904
68 results